Targeted Therapies in Advanced and Metastatic Urothelial Carcinoma

Katims, Andrew B.; Reisz, Peter; Nogueira, Lucas; Truong, Hong; Pietzak, Eugene J.; Kim, Kwanghee; Coleman, Jonathan

doi:10.3390/cancers14215431

Cited by 10 publications

(8 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, exploring the potential of novel agents and combination therapies, especially in the context of drug resistance, is a critical area for future research. The development of therapies targeting specific molecular pathways implicated in bladder cancer progression, such as FGFR3 inhibitors and PARP inhibitors, holds promise for improving treatment outcomes ( 49 ).…”

Section: Discussionmentioning

confidence: 99%

A bibliometric insight into neoadjuvant chemotherapy in bladder cancer: trends, collaborations, and future avenues

Huang,

Liao,

Shen

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

BackgroundNeoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) remains the cornerstone of treatment for muscle-invasive bladder cancer (MIBC). While platinum-based regimens have demonstrated benefits in tumor downstaging and improved long-term survival for selected patients, they may pose risks for those who are ineligible or unresponsive to chemotherapy.ObjectiveWe undertook a bibliometric analysis to elucidate the breadth of literature on NAC in bladder cancer, discern research trajectories, and underscore emerging avenues of investigation.MethodsA systematic search of the Web of Science Core Collection (WoSCC) was conducted to identify articles pertaining to NAC in bladder cancer from 1999 to 2022. Advanced bibliometric tools, such as VOSviewer, CiteSpace, and SCImago Graphica, facilitated the examination and depicted the publication trends, geographic contributions, institutional affiliations, journal prominence, author collaborations, and salient keywords, emphasizing the top 25 citation bursts.ResultsOur analysis included 1836 publications spanning 1999 to 2022, indicating a growing trend in both annual publications and citations related to NAC in bladder cancer. The United States emerged as the predominant contributor in terms of publications, citations, and international collaborations. The University of Texas was the leading institution in publication output. “Urologic Oncology Seminars and Original Investigations” was the primary publishing journal, while “European Urology” boasted the highest impact factor. Shariat, Shahrokh F., and Grossman, H.B., were identified as the most prolific and co-cited authors, respectively. Keyword analysis revealed both frequency of occurrence and citation bursts, highlighting areas of concentrated study. Notably, the integration of immunochemotherapy is projected to experience substantial growth in forthcoming research.ConclusionsOur bibliometric assessment provides a panoramic view of the research milieu surrounding neoadjuvant chemotherapy for bladder cancer, encapsulating the present state, evolving trends, and potential future directions, with a particular emphasis on the promise of immunochemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

A bibliometric insight into neoadjuvant chemotherapy in bladder cancer: trends, collaborations, and future avenues

Huang,

Liao,

Shen

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Advanced and metastatic UC account for the majority of deaths associated with this disease. 16 In a large retrospective study on metastatic upper UC, the most common site of metastasis was identified as the distant lymph nodes, and liver metastasis was found to be a poor prognostic factor, whereas primary tumour resection and chemotherapy were predictors of better survival outcome. 17 The development of cisplatin-based combination chemotherapy has extended median survival from several to 11–15 months.…”

Section: Discussionmentioning

confidence: 99%

“… 17 The development of cisplatin-based combination chemotherapy has extended median survival from several to 11–15 months. 16 However, the prognosis for metastatic patients with no response to primary chemotherapy is poor. 18 In addition, long term treatment with platinum may result in severe adverse effects.…”

Section: Discussionmentioning

confidence: 99%

Real-world retrospective review of monotherapy following platinum-based chemotherapy for metastatic urothelial cancer

et al. 2023

View full text Add to dashboard Cite

Objective To compare estimated survival times of patients who had received maintenance monotherapy with gemcitabine (GEM), or an immuno-oncology (IO) drug (i.e., pembrolizumab or avelumab) or both therapies (one after the other) following platinum-based combination chemotherapy for metastatic urothelial carcinoma (UC) in a real-world setting. Methods For this retrospective study, we included consecutive patients with metastatic UC who had received first-line platinum-based chemotherapy followed by second-line treatment at our centre from March 2008 to June 2020. Results Of the 74 patients identified, 58 had received monotherapy as second line treatment, and 16 had received combination chemotherapy (i.e., non-monotherapy). The estimated median duration of survival was significantly longer in the monotherapy group compared with the non-monotherapy group (29 vs 7 months). Multivariate analysis showed that the outcome of the first-line chemotherapy treatment was the most important prognostic factor for survival. There was no significant difference in survival times between monotherapy with GEM or IO drugs. In addition, survival was significantly prolonged when GEM therapy was administered following IO drugs compared with GEM therapy alone. Conclusion Monotherapy following primary chemotherapy for advanced UC significantly prolonged survival times, and IO drug therapy remained effective when followed by GEM single agent maintenance therapy.

show abstract

“…Urothelial cell carcinoma (UCC, formerly known as transitional cell carcinoma, TCC) is the most common neoplasm of the urinary system. UCC is the most common histologic type of BC and accounts for ~90% of all BC [1][2][3][4]. A number of histologic variants of UCC have been identified, including micropapillary, microcystic, nested, lymphoepitheliomalike, plasmacytoid, sarcomatoid, giant cell, poorly differentiated, lipid rich, clear cell and urothelial carcinoma with divergent differentiation.…”

Section: Introduction 1overviewmentioning

confidence: 99%

“…UCC is defined as the invasion of the cancer cells' basement membrane or lamina propria or deeper by neoplastic cells of urothelial origin. Invasion is defined as 'micro invasion' when the depth of invasion is 2 mm or less [2]. The World Health Organization (WHO) classifies BCs based on differentiation as low grade (grades 1 and 2) or high grade (grade 3) [1].…”

Section: Introduction 1overviewmentioning

confidence: 99%

Current and Emerging Strategies to Treat Urothelial Carcinoma

Rani,

Ignatz-Hoover,

Rana

et al. 2023

Cancers

View full text Add to dashboard Cite

Urothelial cell carcinoma (UCC, bladder cancer, BC) remains a difficult-to-treat malignancy with a rising incidence worldwide. In the U.S., UCC is the sixth most incident neoplasm and ~90% of diagnoses are made in those >55 years of age; it is ~four times more commonly observed in men than women. The most important risk factor for developing BC is tobacco smoking, which accounts for ~50% of cases, followed by occupational exposure to aromatic amines and ionizing radiation. The standard of care for advanced UCC includes platinum-based chemotherapy and programmed cell death (PD-1) or programmed cell death ligand 1 (PD-L1) inhibitors, administered as frontline, second-line, or maintenance therapy. UCC remains generally incurable and is associated with intrinsic and acquired drug and immune resistance. UCC is lethal in the metastatic state and characterized by genomic instability, high PD-L1 expression, DNA damage-response mutations, and a high tumor mutational burden. Although immune checkpoint inhibitors (ICIs) achieve long-term durable responses in other cancers, their ability to achieve similar results with metastatic UCC (mUCC) is not as well-defined. Here, we discuss therapies to improve UCC management and how comprehensive tumor profiling can identify actionable biomarkers and eventually fulfill the promise of precision medicine for UCC patients.

show abstract

Targeted Therapies in Advanced and Metastatic Urothelial Carcinoma

Cited by 10 publications

References 66 publications

A bibliometric insight into neoadjuvant chemotherapy in bladder cancer: trends, collaborations, and future avenues

A bibliometric insight into neoadjuvant chemotherapy in bladder cancer: trends, collaborations, and future avenues

Real-world retrospective review of monotherapy following platinum-based chemotherapy for metastatic urothelial cancer

Current and Emerging Strategies to Treat Urothelial Carcinoma

Contact Info

Product

Resources

About